-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PIPE-307 in Relapsing Remitting Multiple Sclerosis (RRMS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PIPE-307 in Relapsing Remitting Multiple Sclerosis (RRMS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PIPE-307 in Relapsing Remitting Multiple Sclerosis (RRMS) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CCAR-066 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CCAR-066 in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CCAR-066 in Follicular Lymphoma Drug Details: CCAR-066 (CBM.CD20 CAR-T) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CCAR-066 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CCAR-066 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CCAR-066 in Diffuse Large B-Cell Lymphoma Drug Details: CCAR-066...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CCAR-066 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CCAR-066 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CCAR-066 in Marginal Zone B-cell Lymphoma Drug Details: CCAR-066...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CCAR-039 in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CCAR-039 in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CCAR-039 in Primary Mediastinal B-Cell Lymphoma Drug Details: CCAR-039...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nirogacestat Hydrobromide in Soft Tissue Sarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nirogacestat Hydrobromide in Soft Tissue Sarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nirogacestat Hydrobromide in Soft Tissue Sarcoma Drug Details: Nirogacestat...
-
Sector Analysis
NewAttention Deficit Hyperactivity Disorder (ADHD) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Attention Deficit Hyperactivity Disorder (ADHD) Market Report Overview The ADHD market across the 7MM was valued at $11.9 billion in 2022. The market will decline at a CAGR of less than 1% from 2022 to 2032. The 7MM includes the US, France, Germany, Italy, Spain, the UK, and Japan. Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder with specific criteria for children and adults. ADHD is characterized by age-inappropriate, extreme, and impairing levels of inattention and/or hyperactivity and impulsivity. It is...
-
Thematic Analysis
NewState of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update) – Thematic Intelligence
Reasons to buy the ‘State of the Biopharmaceutical Industry 2024’ thematic intelligence report: Highlight the business environment and the industry, regulatory, and macroeconomic trends that are going to shape the biopharmaceutical industry in the next 12 months. Benchmark the impact of major themes on the biopharmaceutical industry in the next 12 months, Identify themes that will have the greatest positive or negative impact in the coming months. Comprehend the opinions of industry respondents on these themes. Predict the industry’s growth prospects...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CCAR-039 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CCAR-039 in Follicular Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CCAR-039 in Follicular Lymphoma Drug Details: CCAR-039 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NBTXR-3 in Recurrent Head And Neck Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NBTXR-3 in Recurrent Head And Neck Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NBTXR-3 in Recurrent Head And Neck Squamous...